MediLifestyle    Last:0.048    -0.001

Consolidation 10 to 1

Engine cold start. Let it warm up first

 

SmallSmall      ( Date: 20-Jun-2023 10:05) Posted: Relax. Next Sinocloud in the making. Small sharebase of only 72 mil after consolidation 10 to 1

 

saw the chart 2022 may time was 35....

might be a multibaggers of 5x to 10x..

tankoksee      ( Date: 22-Jun-2023 16:43) Posted: pre-consolidation was 5/6.... post should be 50-60...tho the high was 58... interesting..with the vast news announced..

 

pre-consolidation was 5/6....

post should be 50-60...tho the high was 58...

interesting..with the vast news announced..

 

Lai liao. $0.035 day high vs day low $0.029

 

This one 50-50% can break out. Needs more volumes and error trades as this one has just consolidated 10 to 1

SmallSmall      ( Date: 22-Jun-2023 13:08) Posted: COLLABORATION AGREEMENT BETWEEN HEALTHPRO MARKETING AND SHINE BIOSCIENCE The Board of Directors (the " Board" or " Directors" ) of Medi Lifestyle Limited (the " Company" , and together with its subsidiaries, the " Group" ) is pleased to announce that the Company&rsquo s indirect wholly owned subsidiary, HealthPro Marketing Sdn Bhd (&ldquo HPM&rdquo ) has entered into a collaboration agreement (the &ldquo Collaboration Agreement&rdquo ) with Shine Bioscience (M) Sdn. Bhd. (&ldquo Shine Bioscience&rdquo ), to promote cellbased therapy wellness tourism, including Human Umbilical-Cord Derived Mesenchymal Stem Cell (UCMSCs) and Mesenchymal Stem Cell-derived Exosomes. Shine Bioscience, the premier provider of wellness tourism programs invites Chinese tourists from China to Malaysia. With their expert team, strategic partnerships, and meticulous attention to detail, Shine Bioscience ensures that every aspect of the wellness tourism programs is thoughtfully tailored to exceed expectations, providing a harmonious fusion of rejuvenation, cultural exploration, and relaxation. Dato Ken Low, Executive Director & CEO of the Company, commented, &ldquo I am delighted to announce this partnership that aims to shape wellness tourism in the Malaysia-China region. By combining cutting-edge cell therapy with luxury hospitality, we are poised to create an extraordinary experience for individuals seeking advanced preventive healthcare solutions, driving innovation and delivering substantial value to our investors." Mr. Gan Chee Huat, Director of the Shine Bioscience, commented, &ldquo This partnership represents a significant milestone for us, as we combine our expertise in regenerative products with the art of crafting transformative wellness experiences. Together, we aim to redefine the boundaries of well-being, offering Chinese tourists an unparalleled journey of rejuvenation, cultural immersion, and relaxation in the captivating landscapes of Malaysia." Shareholders and other investors are reminded to exercise caution while dealing in the shares of the Company. In the event that shareholders and other investors are in doubt when dealing in the shares of the Company, they should consult their bankers, stockbrokers, solicitors or other professional advisers. The Company will make the appropriate announcements as and when there are material developments.

 

COLLABORATION AGREEMENT BETWEEN HEALTHPRO MARKETING AND SHINE BIOSCIENCE The Board of Directors (the " Board" or " Directors" ) of Medi Lifestyle Limited (the " Company" , and together with its subsidiaries, the " Group" ) is pleased to announce that the Company&rsquo s indirect wholly owned subsidiary, HealthPro Marketing Sdn Bhd (&ldquo HPM&rdquo ) has entered into a collaboration agreement (the &ldquo Collaboration Agreement&rdquo ) with Shine Bioscience (M) Sdn. Bhd. (&ldquo Shine Bioscience&rdquo ), to promote cellbased therapy wellness tourism, including Human Umbilical-Cord Derived Mesenchymal Stem Cell (UCMSCs) and Mesenchymal Stem Cell-derived Exosomes. Shine Bioscience, the premier provider of wellness tourism programs invites Chinese tourists from China to Malaysia. With their expert team, strategic partnerships, and meticulous attention to detail, Shine Bioscience ensures that every aspect of the wellness tourism programs is thoughtfully tailored to exceed expectations, providing a harmonious fusion of rejuvenation, cultural exploration, and relaxation. Dato Ken Low, Executive Director & CEO of the Company, commented, &ldquo I am delighted to announce this partnership that aims to shape wellness tourism in the Malaysia-China region. By combining cutting-edge cell therapy with luxury hospitality, we are poised to create an extraordinary experience for individuals seeking advanced preventive healthcare solutions, driving innovation and delivering substantial value to our investors." Mr. Gan Chee Huat, Director of the Shine Bioscience, commented, &ldquo This partnership represents a significant milestone for us, as we combine our expertise in regenerative products with the art of crafting transformative wellness experiences. Together, we aim to redefine the boundaries of well-being, offering Chinese tourists an unparalleled journey of rejuvenation, cultural immersion, and relaxation in the captivating landscapes of Malaysia." Shareholders and other investors are reminded to exercise caution while dealing in the shares of the Company. In the event that shareholders and other investors are in doubt when dealing in the shares of the Company, they should consult their bankers, stockbrokers, solicitors or other professional advisers. The Company will make the appropriate announcements as and when there are material developments.

 

Relax. Next Sinocloud in the making. Small sharebase of only 72 mil after consolidation 10 to 1

 

Today OBK, drop 16%.

On Downtrend, Non-Stop!

 

Be careful this stock got insider trading run up super fast and trap u play with care

hschsc      ( Date: 19-Jun-2023 17:17) Posted: Do this company got hope?  SmallSmall      ( Date: 19-Jun-2023 10:05) Posted: Price dropped because of shares issue from convertible bond or erroreous sale because the share was consolidation 10 to 1.  At current price of $0.034 it is equivalent to $0.0034 pre consolidation. Risk vs return good as it is trading near conversion price of $0.032 CONVERSION OF CONVERTIBLE BONDS INTO 3,125,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT AN ISSUE PRICE OF S$0.032

 

Do this company got hope? 

SmallSmall      ( Date: 19-Jun-2023 10:05) Posted: Price dropped because of shares issue from convertible bond or erroreous sale because the share was consolidation 10 to 1.  At current price of $0.034 it is equivalent to $0.0034 pre consolidation. Risk vs return good as it is trading near conversion price of $0.032 CONVERSION OF CONVERTIBLE BONDS INTO 3,125,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT AN ISSUE PRICE OF S$0.032

 

Price dropped because of shares issue from convertible bond or erroreous sale because the share was consolidation 10 to 1. 
At current price of $0.034 it is equivalent to $0.0034 pre consolidation.

Risk vs return good as it is trading near conversion price of $0.032


CONVERSION OF CONVERTIBLE BONDS INTO 3,125,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT AN ISSUE PRICE OF S$0.032